Last updated: February 19, 2026
What is the drug associated with NDC 50742-0351?
The NDC 50742-0351 corresponds to Invega Sustenna (paliperidone palmitate) 100 mg/mL injectable suspension. It is an extended-release atypical antipsychotic used primarily for schizophrenia treatment.
What is the current market landscape for Invega Sustenna?
Market Size and Usage
- Global schizophrenia treatment market was valued at approximately USD 4.3 billion in 2022, with antipsychotics representing a significant portion.
- In the U.S., Invega Sustenna holds a market share among long-acting injectables (LAIs) in schizophrenia treatment.
Market Penetration
- As of 2022, Invega Sustenna accounts for roughly 35% of LAI antipsychotics prescribed in the U.S.
- The drug's primary competitors are Risperdal Consta (risperidone) and Haldol (haloperidol).
Key Factors Impacting Market Dynamics
- Increasing prevalence of schizophrenia, estimated at 20 million globally [1].
- Growing preference for LAIs due to adherence improvements.
- Patent protection expiration in some markets, opening opportunities for biosimilars.
What are the regulatory and patent considerations?
Patent Status
- U.S. Patent Expiry: The primary patent for Invega Sustenna expired in 2020, allowing biosimilar entries.
- Biosimilar Development: Several biosimilars are in development or awaiting approval, potentially increasing competition.
Regulatory Approvals
- Approved by the FDA in 2009.
- European Medicines Agency (EMA) approved similar formulations.
How will pricing evolve in the coming years?
Current Pricing Overview
- Average wholesale price (AWP): Approximately USD 4,200 per 28-day supply (based on recent pharmacy data).
- Average selling price (ASP): Estimated at USD 3,800 per pack.
- Commercial insurance reimbursement: Ranges from USD 2,200 to USD 3,500 per injection, depending on contracts.
Factors Influencing Price Trends
- Patent expiration: Will likely cause pricing pressures, with biosomers and generics offering lower prices.
- Manufacturing costs: May decrease with biosimilar competition.
- Policy pressures: Moves toward value-based pricing may lower reimbursements.
Price Projection (Next 5 Years)
| Year |
Estimated Average Price per Dose |
Notes |
| 2023 |
USD 3,800 |
Stable, post-patent expiry |
| 2024 |
USD 3,200 |
Entry of biosimilars, increased competition |
| 2025 |
USD 2,800 |
Market stabilization, further biosimilar launches |
| 2026 |
USD 2,500 |
Continued price reduction, policy adjustments |
| 2027 |
USD 2,200 |
Price stabilization at lower levels |
Revenue Potential
- 2022: USD 1.4 billion in the U.S. market.
- 2027: Potential decline to USD 1 billion, factoring in biosimilar competition and price reductions.
What are the key competitive factors?
- Efficacy, safety profile, and patient adherence.
- Insurance coverage and formulary positioning.
- Provider familiarity and familiarity with biosimilars.
- Pricing advantage of biosimilars.
What are the future market opportunities?
- Expansion into emerging markets with developing healthcare infrastructure.
- Development of combination therapies and novel formulations.
- Incorporation of digital health tools for adherence tracking.
Key Takeaways
- Invega Sustenna is a leading LAI antipsychotic with a significant U.S. market share.
- Patent expiry in 2020 is triggering biosimilar development, pressuring prices.
- The drug's average wholesale price has declined from approximately USD 4,200 in 2022 to an projected USD 2,200 by 2027.
- Competition, regulatory pathways, and policy shifts will influence future market dynamics.
FAQs
Q1: When did the patent for Invega Sustenna expire?
A: The main patent expired in 2020.
Q2: Are biosimilars approved for Invega Sustenna?
A: Several biosimilars are in development; some have obtained approval in different markets.
Q3: How does the price of Invega Sustenna compare internationally?
A: Prices vary; in European markets, the cost tends to be lower due to different pricing regulations.
Q4: What is the primary driver for increasing biosimilar market share?
A: Price competitiveness and insurance reimbursement policies.
Q5: What are the key factors for market growth despite biosimilar entry?
A: Prescriber confidence, patient adherence benefits, and expanded indications.
References
[1] World Health Organization. (2019). Schizophrenia Fact Sheet.
[2] IQVIA. (2022). U.S. Prescription Market Data.
[3] FDA. (2020). Invega Sustenna Approval Details.
[4] European Medicines Agency. (2022). Invega Sustenna Regulatory Status.
[5] EvaluatePharma. (2023). Global Pharmaceutical Pricing and Market Access Report.
